- Correction
- Open Access
- Published:
Correction to: Butyrophilin-like 9 expression is associated with outcome in lung adenocarcinoma
BMC Cancer volume 21, Article number: 1146 (2021)
Correction to: BMC Cancer 21, 1096 (2021)
https://doi.org/10.1186/s12885-021-08790-9
Following publication of the original article [1], the authors identified an error in Fig. 2. The gene BTN3A1 has Chinese text characters, and BTN3A2, BTN3A3, BTNL2, BTNL3, BTNL8, BTNL9, BTNL10, and SKINTL are not marked.
BTNL9 Expression and prognosis in LUAD. A BTNs expression panel in LUAD tissues compared with adjacent tissues in GEPIA database. B Correlation between BTNL8 and BTNL9 expression and LUAD clinical stages, N stage, and p53 mutation in the UALCAN database (BTNL8 expression compared with LUAD clinical stages (Normal-vs-Stage1, P = 1.01E-04; Normal-vs-Stage2, P = 7.08E-03; Normal-vs-Stage3, P = 1.36E-04; Normal-vs-Stage4, P = 1.78E-08), N stage (Normalvs-N0, P = 6.56E-04; Normal-vs-N1, P = 8.27E-10; Normal-vs-N2, P = 5.96E-04; Normal-vs-N3, P = 1.97E-10; N0-vs-N1, P = 3.27E-03; N0-vs-N3, P = 6.79E-04), and p53 status (Normal-vs-T P53-Mutant, P = 1.27E-06; Normal-vs-T P53-NonMutant, P = 1.80E-03). BTNL9 expression comparison with LUAD clinical stages (Normal-vsStage1, P = 1.21E-12; Normal-vs-Stage2, P = 3.60E-13; Normal-vs-Stage3, P = 2.40E-12; Normal-vs-Stage4, P = 2.25E-12), N stage (Normal-vs-N0, P = 1.08E-12; Normal-vs-N1, P = 1.85E-12; Normal-vs-N2, P = 1.02E-12; Normal-vs-N3, P = 1.67E-12; N0-vs-N1, P = 1.02E-03; N2-vs-N3, P = 3.01E-02), and P53 status (Normal-vs-T P53-Mutant, P = 1.85E-12; Normal-vs-T P53-NonMutant, P = 4.10E-12; T P53-Mutant-vs-T P53-NonMutant, P = 1.77E-04)). C Correlation between BTNL8 and BTNL9 expression with overall survival of LUAD using GEPIA database. D Correlation between BTNL9 expression and LUAD overall survival using OncoLnc, UALCAN, and KM plotter databases. *: P-value < 0.05; **: P-value < 0.01; ***: P-value < 0.001
Reference
Ma W, Liang J, Mo J, et al. Butyrophilin-like 9 expression is associated with outcome in lung adenocarcinoma. BMC Cancer. 2021;21:1096. https://doi.org/10.1186/s12885-021-08790-9.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Ma, W., Liang, J., Mo, J. et al. Correction to: Butyrophilin-like 9 expression is associated with outcome in lung adenocarcinoma. BMC Cancer 21, 1146 (2021). https://doi.org/10.1186/s12885-021-08874-6
Published:
DOI: https://doi.org/10.1186/s12885-021-08874-6